tbuckley/cabot-search huggingface dataset:
Abstract 17036: Cardiomyocyte Krüppel-Like Factor 5 Regulates Ceramide Biosynthesis and Promotes Systolic Dysfunction in Ischemic Heart Failure
Authors: Matthew K Hoffman, Ioannis Kyriazis, Dimitra Palioura, Maria Cimini, Sudarsan Rajan, Erhe Gao, Nikolas Nikolaidis, Christian Schulze, Ira J Goldberg, Raj Kishore, Vincent W Yang, Thomas Bannister, Agnieszka Bialkowska, Craig Selzman, Stavros G Drakos, Konstantinos Drosatos
Journal: Circulation (2020)

Introduction: Our lab previously showed that cardiomyocyte Krüppel-like factor (KLF)-5 regulates cardiac fatty acid oxidation. Various studies have associated heart failure with altered cardiac fatty acid oxidation and lipotoxicity. Hypothesis: Aberrant regulation of KLF5 contributes to pathophysiology and metabolic perturbations in ischemic heart failure. Methods and Results: Analysis of KLF5 mRNA and protein levels in human ischemic heart failure samples and in rodent models 2- and 4-weeks post-myocardial infarction (MI) showed significantly increased KLF5 expression. To investigate the involvement of KLF5 in the pathophysiology of ischemic heart failure, we treated mice that were subjected to MI with a pharmacological KLF5 inhibitor (ML264). ML264 increased ejection fraction and reduced diastolic volume. Likewise, mice with cardiomyocyte-specific KLF5 deletion (αMHC-KLF5 -/- mice) were protected from ischemic heart failure. Lipidomic analysis by LC-MS/MS showed that αMHC-KLF5 -/- mice after MI had lower myocardial ceramide levels compared with control mice with MI. Accordingly, the expression of cardiac SPTLC1 and SPTLC2, which regulate de novo ceramide biosynthesis, was higher in control mice with MI and lower in αMHC-KLF5 -/- mice with MI. KLF5 overexpression in HL1 cardiomyocytes increased SPTLC1 and SPTLC2 mRNA and protein levels. ChIP-qPCR and luciferase promoter assays showed that KLF5 activates the promoters of these genes via direct binding. To assess the transcriptional effects of KLF5 independent from other changes that occur with MI, we generated a mouse model of inducible (Dox-ON), cardiomyocyte-specific expression of KLF5 (αMHC-rtTA-KLF5). Systolic dysfunction was evident 2-weeks following KLF5 induction. Heart tissue from these mice exhibited increased SPTLC1 and SPTLC2 mRNA and protein levels, and inhibition of SPT using myriocin suppressed myocardial ceramide levels and alleviated systolic dysfunction. Conclusions: KLF5 is induced during the development of ischemic heart failure in humans and mice, and stimulates expression of SPTLC1 and SPTLC2 that promote ceramide biosynthesis. KLF5 inhibition emerges as a novel therapeutic target to protect against ischemic heart failure.
Abstract 15587: Pericardial Tamponade in Patients With Influenza Infection: A Systematic Review of Published Cases
Authors: Rupak Desai, Jilmil S Raina, Vikram Itare, Akhil Jain, Sandeep Singh, Rushik Bhuva, Faizan Ahmad Malik, Vraj Shah, Falah A Hassan, Rajesh Sachdeva, Gautam Kumar
Journal: Circulation (2020)

Introduction: Literature reported cardiac tamponade in patients with influenza virus infection, which incited us to understand patient-level demographics, courses and outcomes. Methods: Systematic literature search was performed until May 2020 to review post-influenza cardiac tamponade cases. Results: Twenty five publications reported 28 patients (M:F::12:15, age range: 4-69 yrs, 9 pediatric) who had post-influenza cardiac tamponade as shown in Table 1 . Nine (32.1%) patients had dyspnea and 7 (25%) had chest pain. Onset of tamponade after flu ranged from 1 day-6 weeks. 22 (78.5%) and 3 (10.7%) were infected with Influenza A and B strains respectively. Troponin-T (n=7) ranged from 0.03 ng/dL-10.50 ng/dL. Twelve (42.8%) patients were treated with influenza therapy; 8 (28.5%) with Pseltamivir, 2 (7.1%) with Oseltamivir followed by Peramivir, 1 (3.5%) with Zanamivir, 1 (3.5%) with Zanamivir followed by Peramivir. Pericardiocentesis was done in 25 (89.2%) patients. Seventeen (57.1%) patients required mechanical circulatory/respiratory support: 13 intubations, 3 ECMO, 2 CPR, 1 external defibrillation and 1 noninvasive ventilation. Twenty-three (82.1%) patients recovered while 4 (14.2%) patients died. Conclusion: This systematic review of patient-level data showed high recovery rate with early diagnosis and timely pericardiocentesis and nearly 14% of mortality rate.
Author Correction: The NCI Genomic Data Commons
Authors: Allison P. Heath, Vincent Ferretti, Stuti Agrawal, Maksim An, James C. Angelakos, Renuka Arya, Rosita Bajari, Bilal Baqar, Justin H. B. Barnowski, Jeffrey Burt, Ann Catton, Brandon F. Chan, Fay Chu, Kim Cullion, Tanja Davidsen, Phuong-My Do, Christian Dompierre, Martin L. Ferguson, Michael S. Fitzsimons, Michael Ford, Miyuki Fukuma, Sharon Gaheen, Gajanan L. Ganji, Tzintzuni I. Garcia, Sameera S. George, Daniela S. Gerhard, Francois Gerthoffert, Fauzi Gomez, Kang Han, Kyle M. Hernandez, Biju Issac, Richard Jackson, Mark A. Jensen, Sid Joshi, Ajinkya Kadam, Aishmit Khurana, Kyle M. J. Kim, Victoria E. Kraft, Shenglai Li, Tara M. Lichtenberg, Janice Lodato, Laxmi Lolla, Plamen Martinov, Jeffrey A. Mazzone, Daniel P. Miller, Ian Miller, Joshua S. Miller, Koji Miyauchi, Mark W. Murphy, Thomas Nullet, Rowland O. Ogwara, Francisco M. Ortuño, Jesús Pedrosa, Phuong L. Pham, Maxim Y. Popov, James J. Porter, Raymond Powell, Karl Rademacher, Colin P. Reid, Samantha Rich, Bessie Rogel, Himanso Sahni, Jeremiah H. Savage, Kyle A. Schmitt, Trevar J. Simmons, Joseph Sislow, Jonathan Spring, Lincoln Stein, Sean Sullivan, Yajing Tang, Mathangi Thiagarajan, Heather D. Troyer, Chang Wang, Zhining Wang, Bedford L. West, Alex Wilmer, Shane Wilson, Kaman Wu, William P. Wysocki, Linda Xiang, Joseph T. Yamada, Liming Yang, Christine Yu, Christina K. Yung, Jean Claude Zenklusen, Junjun Zhang, Zhenyu Zhang, Yuanheng Zhao, Ariz Zubair, Louis M. Staudt, Robert L. Grossman
Journal: Nature Genetics (2021)
Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes
Authors: David D Berg, Stephen D Wiviott, Benjamin M Scirica, Erica Goodrich, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, JOHN WILDING, Per Johanson, Anna Maria Langkilde, Eugene Braunwald, Marc S Sabatine, David A Morrow
Journal: Circulation (2020)

Introduction: Heart failure (HF) is a prognostically important complication of T2DM, the risk of which can be reduced by SGLT2 inhibitors. Clinical factors and circulating biomarkers of myocardial injury and hemodynamic stress predict risk of hosp for HF (HHF) in pts with T2DM. Aim: We aimed to develop and validate a biomarker-based risk score for HHF in pts with T2DM and to assess whether this score can identify high-risk pts with T2DM who have the greatest reduction in HHF risk with SGLT2 inhibition. Methods: Blood samples were prospectively collected from pts enrolled in SAVOR-TIMI 53 and DECLARE-TIMI 58 at randomization; high-sensitivity troponin T (hsTnT) and N-terminal B-type natriuretic peptide (NT-proBNP) were measured. We derived a risk score in 6106 pts with T2DM in the placebo arm of SAVOR-TIMI 53. Candidate variables (n=27) were assessed using Cox regression. The strongest indicators of HHF risk (based on Wald χ;2 values) were selected for inclusion and assigned integer weights. We externally validated the score in 7251 T2DM pts in the placebo arm of DECLARE-TIMI 58. Hazard ratios (HR) and absolute risk reductions (ARR) in HHF with the SGLT2 inhibitor dapagliflozin were assessed by baseline risk group. Results: The strongest independent indicators of HHF risk were NT-proBNP and hsTnT concentrations, and prior HF (each p&lt;0.001). A risk score using these 3 variables identified a strong gradient of HHF risk (p-trend &lt;0.001) in both the derivation and validation cohorts, with c-indices of 0.87 and 0.84, respectively. HRs with dapagliflozin were similar across risk groups (p-int = 0.64); however, ARRs were greater in those at higher baseline risk (p-trend &lt;0.001), with high- (10-13 points) and very high-risk (14+ points) pts having 3.2% and 4.4% ARRs in KM estimates of HHF at 4 yrs, respectively ( Fig ). Conclusions: A novel biomarker-based risk score for HHF in pts with T2DM identifies pts at higher risk of HHF who derive greater absolute benefit from SGLT2 inhibitors.
Abstract 13401: Prothymosin Alpha (Protα) Associates With Pathogenesis and Sex Predisposition in Rheumatic Heart Valve Disease
Authors: Livia Passos, Mark C Blaser, Dayanna Romero, Dakota Becker Greene, Adrien Lupieri, Galina K Sukhova, Jacob P Dal-bianco, Peter Libby, Sasha A Singh, Masanori Aikawa, Robert A Levine, Maria Do Carmo P Nunes, Elena Aikawa
Journal: Circulation (2020)

Introduction: Acute rheumatic fever (ARF) results from autoimmune responses to group A streptococcus. ARF can cause chronic rheumatic heart valve disease (RHVD), a major public health burden in low- and middle-income countries. Although ARF affects both sexes equally, females have a higher prevalence of RHVD. We identified a target protein, ProTα, that may contribute to pathophysiology of and gender predisposition in RHVD. Estradiol regulates ProTα, which influences transcriptional activity of the estrogen receptor (ER). Methods: Human heart valves (n=120) obtained from heart transplantation and valve replacement surgeries, including non-diseased mitral and aortic valves (NDMV and NDAV, n=17/group), rheumatic mitral and aortic valves (RMVD, n=45; RAVD, n=8) and calcifying valves from patients with calcific aortic valve disease (CAVD, n=33) underwent proteomic and network analyses, and immunohistochemical assessment of CD68, CD4, CD8 and ProTα. ProTα levels were measured in plasma and peripheral mononuclear cells (PBMCs) from RHVD patients and healthy donors (n=14/group) by ELISA and flow cytometry. Results: A comparison of proteomes from NDMV and NDAV established the baseline differences between valve types. 12 proteins were enriched (q&lt;0.05) in NDMV that may indicate the mitral valve predisposition to RVHD. Proteome analysis of non-diseased and diseased valves (NDMV vs RMVD, NDAV vs RAVD) identified a total of 213 proteins enriched in RHVD (q&lt;0.05). The expression of the 12 NDMV-enriched proteins were evaluated across the 213 proteins enriched in diseased valves, resulting in the identification of ProTα common to both the RMVD and RAVD proteomes, but absent in CAVD. Additional KEGG pathway enrichment analyses linked 6 among 213 proteins with the estrogen signaling pathway (p&lt;0.05). Immunoreactive ProTα colocalized with T CD8 cells in RHVD. ProTα and ERα also correlated strongly in circulating T CD8 cells in RHVD (p&lt;0.05). ProTα plasma levels were higher in RHVD patients than healthy individuals (2 fold, p&lt;0.05). Conclusion: We propose that ProTα is a novel contributor to the immunopathogenesis of RHVD and may regulate sex predisposition in this disease.
Abstract P152: Self-reported Physical Activity And Outcomes In Individuals With Chronic Kidney Disease
Authors: Jacob Bruinius, Mary Hannan, Jinsong Chen, Julia Brown, Mayank Kansal, Natalie Meza, Milda Saunders, Jiang He, Ana Ricardo, James Lash
Journal: Circulation (2021)

Background: In the general population, higher levels of physical activity are associated with lower risk for cardiovascular events and mortality. Although individuals with CKD are less physically active than individuals without CKD and at increased cardiovascular risk, the association between physical activity and outcomes has not been extensively evaluated in this population. Hypothesis: Lower levels of physical activity will be associated with an increased risk for cardiovascular events and mortality. Methods: We used data from 3935 participants in the Chronic Renal Insufficiency Cohort (CRIC) Study, an ongoing multi-center prospective observational study of adults with CKD enrolled between 2003 and 2008. Self-reported physical activity was assessed at study entry using a self-reported survey. We evaluated two predictors: walking pace and moderate-to-vigorous physical activity (MVPA) MET-hours per week. Outcomes included physician-adjudicated myocardial infarction (MI), stroke, congestive heart failure (CHF), and cardiovascular (CV) death. Cox proportional hazards were used to assess the association of physical activity with outcomes. Results: At baseline, mean age was 57.7 years, 45.2% (1777 of 3935) were women, 33.4% (1314 of 3935) had self-reported cardiovascular disease, mean eGFR was 44.9 ml/min/m 2 , 11.7% (459 of 3914) were in the fastest walk pace group (&gt;3 mph) and median MVPA was 39.0 MET-hours per week. During a median follow-up of 8.9 years, the number of events was 477 for MI, 230 stroke, 843 CHF, and 1022 CV deaths. In fully adjusted models, fastest walk pace was associated with lower risk for each outcome. Those in the highest MVPA quartile had lower risk for MI and CV death, but not stroke or CHF, compared to those who were least active ( Table 1 ). Conclusion: In this cohort of adults with CKD, higher physical activity was protective against cardiovascular events and cardiovascular mortality, which may have important implications for clinical practice and the design of future studies.
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
Authors: Timo Vesikari, Joanne M Langley, Nathan Segall, Brian J Ward, Curtis Cooper, Guillaume Poliquin, Bruce Smith, Soren Gantt, Janet E McElhaney, Marc Dionne, Pierre van Damme, Isabel Leroux-Roels, Geert Leroux-Roels, Nathalie Machluf, Johanna N Spaans, Bebi Yassin-Rajkumar, David E Anderson, Vlad Popovic, Francisco Diaz-Mitoma, Timo Vesikari, Joanne M Langley, Soren Gantt, Marc Dionne, Janet McElhaney, Bruce Rankin, Carl Griffin, Mark Turner, Judith Kirstein, Barbara E Rizzardi, Hayes Williams, Anitta Ahonen, Olli Henriksson, Benita Ukkonen, Marita Paassilta, Nathan Segall, Brian J Ward, Curtis Cooper, Guillaume Poliquin, Bruce Smith, Pierre Van Damme, Isabel Leroux-Roels, Geert Leroux-Roels, Nathalie Machluf, Johanna N Spaans, Bebi Yassin-Rajkumar, David E Anderson, Vlad Popovic, Francisco Diaz-Mitoma
Journal: The Lancet Infectious Diseases (2021)
Biomimetic tubular scaffold with heparin conjugation for rapid degradation in in situ regeneration of a small diameter neoartery
Authors: Renato S. Navarro, Longtan Jiang, Yang Ouyang, Jiawen Luo, Zhiyong Liu, Ying Yang, Ping Qiu, Kenichi Kuroda, Y. Eugene Chen, Peter X. Ma, Bo Yang
Journal: Biomaterials (2021)
Abstract 13393: The Genetic Architecture of Plasma Kynurenine Points to Mechanisms Underlying Its Association With Cardiovascular Diseases
Authors: Minoo Sadat Bagheri Naraghi, Mingjian Shi, Chuan Wang, Jonathan D. Mosley, Jane F Ferguson
Journal: Circulation (2020)

Background: The etiological mechanisms accounting for epidemiological associations between biomarkers and cardiovascular diseases (CVD) are often poorly defined. One example is the metabolite kynurenine, which has been associated with diverse inflammatory-related disease including CVD. We leveraged genetic approaches to elucidate the underlying mechanisms and possible causal relationships accounting for the kynurenine-CVD association. Methods: In this phenome-wide association study (PheWAS), we identified genetic predictors of plasma kynurenine from published genome-wide association studies. We explored associations between both the individual variants and a kynurenine polygenic risk score (PRS) and diseases including heart disease, atherosclerosis, and myocardial infarction in genotyped populations including UK Biobank (n= 456422), Vanderbilt BioVU (n=62,303) and Electronic Medical Records and Genetics (eMERGE) (n=32,324). We applied both single-variant and multi-variant approaches using multivariable logistic regression models. Results: There were no disease associations with a kynurenine PRS, indicating that plasma kynurenine is not a direct mediator of cardiovascular disorders. However, single-variant association analyses identified a robust signal with the kynurenine-associated missense variant in SH2B3 (rs3184504) and myocardial infarction, atherosclerosis of the extremities, peripheral vascular disease , chronic ischemic heart disease , and congestive heart failure (CHF) (all with FDR q&lt;0.05). These findings were replicated in the UK Biobank data. In mice, loss of SH2B3 was associated with significant differences in plasma and tissue levels of kynurenine. Conclusions: Plasma kynurenine may not be causal mediator of cardiovascular disorders. However, the observed relationship between kynurenine and CVD phenotypes in epidemiological studies may be driven through SH2B3 mechanisms, the gene implicated as a novel genetic regulator of kynurenine.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Authors: Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sarah Erridge, Michael A Vogelbaum, Anna K Nowak, Jean Français Baurain, Warren P Mason, Helen Wheeler, Olivier L Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Iris de Heer, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim French, Brigitta G Baumert
Journal: The Lancet Oncology (2021)
Abstract 17013: Voltage Resolution of Standard Bipolar and Omnipolar Ventricular Electrograms
Authors: Jason T Jacobson, Gautam Natarajan, D. Curtis Deno, Daniel Reade, Khaled Qanud, Daniel O Cervantes, Emanuele Pizzo, Sei Iwai, Marcello Rota
Journal: Circulation (2020)

Introduction: Standard bipolar voltage (BiV) mapping is dependent on bipole axis orientation compared to the direction of the activation wavefront. In contrast, omnipolar mapping technology (OmniT) allows for direction-independent voltage measurement, yielding a maximum for each site sampled. However, it is unclear if normal voltage values are the same for BiV and OmniT. Hypothesis: To determine whether electrical signal obtained with OmniT are greater than BiV, using a single 4x4 grid array catheter (HD Grid) inserted in the left ventricle (LV) of an experimental animal. Methods: HD Grid consists of 4 splines, allowing for orthogonal bipoles along (AL) a single spline and across (AC) adjacent splines, allowing for simultaneous OmniT and BiV evaluation. Animals (n=3) underwent transseptal LV mapping during sinus rhythm (SR) and right ventricular pacing (RVP) using HD Grid (4mm interelectrode spacing). Abbott Precision research software was used to generate electroanatomic maps. Peak-to-peak voltage data for OmniT and BiV, both along and across the splines, were exported to a spreadsheet. Data were normalized via log transformation and compared with t-test. Results: Mean voltages and 95% confidence interval for OmniT were consistently greater than BiV AL and AC for both SR and RVP (p&lt;0.05), while BiV AL and AC were comparable. No difference was seen when comparing each method during SR and RVP. The absolute BiV difference due to orientation was significant. See Table. Conclusions: Amplitude of OmiT electorgrams are greater with respect to BiV, which is consistent with the ability of omnipolar technology to capture maximal signals independently from waveform direction. This should be taken into account when determining the optimal OmniT value for ventricular scar.
Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States
Authors: Rishi K. Wadhera, Jose F. Figueroa, Fatima Rodriguez, Michael Liu, Wei Tian, Dhruv S. Kazi, Yang Song, Robert W. Yeh, Karen E. Joynt Maddox
Journal: Circulation (2021)

Cardiovascular deaths increased during the early phase of the COVID-19 pandemic in the United States. However, it is unclear whether diverse racial/ethnic populations have experienced a disproportionate rise in heart disease and cerebrovascular disease deaths.We used the National Center for Health Statistics to identify heart disease and cerebrovascular disease deaths for non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, and Hispanic individuals from March to August 2020 (pandemic period), as well as for the corresponding months in 2019 (historical control). We determined the age- and sex-standardized deaths per million by race/ethnicity for each year. We then fit a modified Poisson model with robust SEs to compare change in deaths by race/ethnicity for each condition in 2020 versus 2019.There were a total of 339 076 heart disease and 76 767 cerebrovascular disease deaths from March through August 2020, compared with 321 218 and 72 190 deaths during the same months in 2019. Heart disease deaths increased during the pandemic in 2020, compared with the corresponding period in 2019, for non-Hispanic White (age-sex standardized deaths per million, 1234.2 versus 1208.7; risk ratio for death [RR], 1.02 [95% CI, 1.02-1.03]), non-Hispanic Black (1783.7 versus 1503.8; RR, 1.19 [95% CI, 1.17-1.20]), non-Hispanic Asian (685.7 versus 577.4; RR, 1.19 [95% CI, 1.15-1.22]), and Hispanic (968.5 versus 820.4; RR, 1.18 [95% CI, 1.16-1.20]) populations. Cerebrovascular disease deaths also increased for non-Hispanic White (268.7 versus 258.2; RR, 1.04 [95% CI, 1.03-1.05]), non-Hispanic Black (430.7 versus 379.7; RR, 1.13 [95% CI, 1.10-1.17]), non-Hispanic Asian (236.5 versus 207.4; RR, 1.15 [95% CI, 1.09-1.21]), and Hispanic (264.4 versus 235.9; RR, 1.12 [95% CI, 1.08-1.16]) populations. For both heart disease and cerebrovascular disease deaths, Black, Asian, and Hispanic populations experienced a larger relative increase in deaths than the non-Hispanic White population (interaction term, P<0.001).During the COVID-19 pandemic in the United States, Black, Hispanic, and Asian populations experienced a disproportionate rise in deaths caused by heart disease and cerebrovascular disease, suggesting that these groups have been most impacted by the indirect effects of the pandemic. Public health and policy strategies are needed to mitigate the short- and long-term adverse effects of the pandemic on the cardiovascular health of diverse populations.
多発性骨髄腫細胞にアポトーシスを誘発する新しいNF-kb阻害剤:プロテアソーム阻害剤およびin vitroおよびin vivo分析との比較
Authors: Tatetsu H, Hata H, Nakamura M, Okuno Y, Matsuno F, Umezawa K, Sonoki T, Mitsuya H
Journal: Blood (2003)
Transthyretin Genetic Testing
Authors: Arjun Sinha, Elizabeth M. McNally, Sadiya S. Khan
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal